HighTower Trust’s AtriCure ATRC Stock Holding History

HighTower Trust’s Portfolio ATRC Stock Details ATRC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-6,432	Closed	-$1.36K	–	234
2022 Q2	$1.36K	Buy	+6,432	New	+$305K	0.14%	85

Other funds holding ATRC

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

HighTower Trust's ATRC Position: Q3 2022 in Review

HighTower Trust sold out of AtriCure (ATRC) in Q3 2022, closing a stake of 6,432 shares — an estimated $1.36K sold.

HighTower Trust first reported a position in ATRC in Q2 2022 and held it in 1 quarter. The position peaked at $1.36K in Q2 2022. 214 funds tracked by Wall St. Rank hold ATRC as of Q3 2022.

HighTower Trust reported no remaining AtriCure position as of Q3 2022 after selling out during the quarter.
HighTower Trust sold 6,432 AtriCure shares in Q3 2022, an estimated $1.36K.
HighTower Trust first reported a position in AtriCure in Q2 2022 and held it in 1 quarter.
HighTower Trust's AtriCure position peaked at $1.36K in Q2 2022.
214 funds tracked by Wall St. Rank held AtriCure as of Q3 2022.

Based on HighTower Trust's 13F filing for Q3 2022, filed 7 Oct 2022.